Challenge
A pre-commercial biotech with 28 months of cash and a 36-month Phase 3 readout faced existential trade-offs. The executive team needed to prioritize programs and optimize the portfolio to extend runway.
Approach
Scimitar designed and facilitated a two-day ELT workshop that combined quantitative modeling with real-time polling to assess portfolio risk, probability of success, and strategic fit. Scenario planning revealed opportunities to deprioritize high-cost discovery programs in favor of promising assets with nearer-term readouts.
Impact
The ELT reached full alignment, redirected investment to a backup molecule that validated their discovery platform, and extended runway by more than two years. The process became a repeatable strategic-planning tool.
